EMA Authorised: Revatio (sildenafil) — Upjohn EESV

View source ↗

Summary

EMA authorised Revatio (sildenafil) for use in hypertension and pulmonary arterial hypertension, with Upjohn EESV as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Pulmonary Arterial Hypertension

Drugs mentioned

• REVATIO (SILDENAFIL CITRATE)

Snippet

Status: Authorised. Therapeutic area: Hypertension, Pulmonary. MAH: Upjohn EESV. Decision date: 15/09/2025